Wykoff CC - Search Results

1

Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial.

Brown DM, Wykoff CC, Boyer D, Heier JS, Clark WL, Emanuelli A, Higgins PM, Singer M, Weinreich DM, Yancopoulos GD, Berliner AJ, Chu K, Reed K, Cheng Y, Vitti R. Brown DM, et al. Among authors: wykoff cc. JAMA Ophthalmol. 2021 Sep 1;139(9):946-955. doi: 10.1001/jamaophthalmol.2021.2809. JAMA Ophthalmol. 2021. PMID: 34351414 Free PMC article. Clinical Trial.

2

SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results.

Wykoff CC, Brown DM, Chen E, Major JC, Croft DE, Mariani A, Wong TP; SAVE Study Group. Wykoff CC, et al. Ophthalmic Surg Lasers Imaging Retina. 2013 Mar-Apr;44(2):121-6. doi: 10.3928/23258160-20130313-04. Ophthalmic Surg Lasers Imaging Retina. 2013. PMID: 23510037 Clinical Trial.

3

Comparison of spectral-domain and time-domain optical coherence tomography in the detection of neovascular age-related macular degeneration activity.

Major JC Jr, Wykoff CC, Mariani AF, Chen E, Croft DE, Brown DM. Major JC Jr, et al. Among authors: wykoff cc. Retina. 2014 Jan;34(1):48-54. doi: 10.1097/IAE.0b013e3182965743. Retina. 2014. PMID: 23764967 Clinical Trial.

4

Two Year SAVE Outcomes: 2.0 mg ranibizumab for recalcitrant neovascular AMD.

Wykoff CC, Brown DM, Croft DE, Wong TP. Wykoff CC, et al. Ophthalmology. 2013 Sep;120(9):1945-6.e1. doi: 10.1016/j.ophtha.2013.06.030. Ophthalmology. 2013. PMID: 24001533 Clinical Trial. No abstract available.

5

What is the optimal timing for rhegmatogenous retinal detachment repair?

Wykoff CC, Flynn HW Jr, Scott IU. Wykoff CC, et al. JAMA Ophthalmol. 2013 Nov;131(11):1399-400. doi: 10.1001/jamaophthalmol.2013.4505. JAMA Ophthalmol. 2013. PMID: 24008508 No abstract available.

6

Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial).

Wykoff CC, Brown DM, Maldonado ME, Croft DE. Wykoff CC, et al. Br J Ophthalmol. 2014 Jul;98(7):951-5. doi: 10.1136/bjophthalmol-2013-304736. Epub 2014 Feb 11. Br J Ophthalmol. 2014. PMID: 24518078 Free PMC article. Clinical Trial.

7

Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema.

Campochiaro PA, Wykoff CC, Shapiro H, Rubio RG, Ehrlich JS. Campochiaro PA, et al. Among authors: wykoff cc. Ophthalmology. 2014 Sep;121(9):1783-9. doi: 10.1016/j.ophtha.2014.03.021. Epub 2014 Apr 24. Ophthalmology. 2014. PMID: 24768239 Clinical Trial.

8

Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial.

Brown DM, Wykoff CC, Wong TP, Mariani AF, Croft DE, Schuetzle KL; RAVE Study Group. Brown DM, et al. Among authors: wykoff cc. Retina. 2014 Sep;34(9):1728-35. doi: 10.1097/IAE.0000000000000191. Retina. 2014. PMID: 24914476 Clinical Trial.

9

Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study.

Campochiaro PA, Wykoff CC, Singer M, Johnson R, Marcus D, Yau L, Sternberg G. Campochiaro PA, et al. Among authors: wykoff cc. Ophthalmology. 2014 Dec;121(12):2432-42. doi: 10.1016/j.ophtha.2014.06.011. Epub 2014 Jul 21. Ophthalmology. 2014. PMID: 25060610 Clinical Trial.

10

Progressive retinal nonperfusion in ischemic central retinal vein occlusion.

Wykoff CC, Brown DM, Croft DE, Major JC Jr, Wong TP. Wykoff CC, et al. Retina. 2015 Jan;35(1):43-7. doi: 10.1097/IAE.0000000000000277. Retina. 2015. PMID: 25102193 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

299 results

Search Page